INS and type 2 diabetes mellitus: Our findings indicate that SZ-A, as a new type 2 diabetes therapy, promotes insulin secretion and provides more protection of β cells by preventing dedifferentiation in vivo and in vitro, and also prevents apoptosis in high glucose and palmitic acid treated insulinoma cell line.